StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma r&d expenses

Research and development expenses are spending on new products and technology.

Xeris Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $34.81M, up 25.3% year over year. For fiscal 2025 it was $31.17M, up 21.9% from the year before. The highest annual figure on record is $31.17M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$31.17M+21.9%
FY2024Dec 31, 2024$25.56M+14.4%
FY2023Dec 31, 2023$22.34M+6.6%
FY2022Dec 31, 2022$20.97M-16.7%
FY2021Dec 31, 2021$25.16M+20.3%
FY2020Dec 31, 2020$20.92M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.67M+32.5%
Q1 FY2026Mar 31, 2026$8.78M+13.3%
Q4 FY2025Dec 31, 2025$7.87M+29.3%
Q3 FY2025Sep 30, 2025$7.48M+27.1%
Q2 FY2025Jun 30, 2025$8.06M+39.9%
Q1 FY2025Mar 31, 2025$7.75M-0.9%
Q4 FY2024Dec 31, 2024$6.09M-4.5%
Q3 FY2024Sep 30, 2024$5.89M+17.0%
Q2 FY2024Jun 30, 2024$5.76M-5.4%
Q1 FY2024Mar 31, 2024$7.82M+61.7%
Q4 FY2023Dec 31, 2023$6.38M+28.8%
Q3 FY2023Sep 30, 2023$5.03M-16.7%
Q2 FY2023Jun 30, 2023$6.09M+63.7%
Q1 FY2023Mar 31, 2023$4.84M-22.6%
Q4 FY2022Dec 31, 2022$4.96M-50.9%
Q3 FY2022Sep 30, 2022$6.04M+6.7%
Q2 FY2022Jun 30, 2022$3.72M-30.9%
Q1 FY2022Mar 31, 2022$6.25M+55.0%
Q4 FY2021Dec 31, 2021$10.08M+97.3%
Q3 FY2021Sep 30, 2021$5.66M+46.1%
Q2 FY2021Jun 30, 2021$5.38M–
Q1 FY2021Mar 31, 2021$4.03M–
Q4 FY2020Dec 31, 2020$5.11M–
Q3 FY2020Sep 30, 2020$3.88M–

More Xeris Biopharma figures

See a number that looks wrong?